“…Benzocaine HCl (BEN) is the ethyl ester of 4-amino benzoic acid (ethyl 4-aminobenzoate) in HCl salt used as a local anaesthetic for supercial anaesthesia, for the local and temporal relief of pain related to, among other disorders, buccal affections. 1 Besides being officially available in USP 2 and BP 3 pharmacopeia, BEN was determined by spectrophotometric [25][26][27][28] and HPLC methods. 14,[29][30][31] Also, BEN has been analyzed in the presence of its degradation product by HPLC.…”
Two validated, sensitive and highly selective stability-indicating methods were adopted for the simultaneous quantitative determination of antipyrine (ANT) and benzocaine HCl (BEN) in the presence of the degradation product of benzocaine HCl [p-aminobenzoic acid (PABA)].
“…Benzocaine HCl (BEN) is the ethyl ester of 4-amino benzoic acid (ethyl 4-aminobenzoate) in HCl salt used as a local anaesthetic for supercial anaesthesia, for the local and temporal relief of pain related to, among other disorders, buccal affections. 1 Besides being officially available in USP 2 and BP 3 pharmacopeia, BEN was determined by spectrophotometric [25][26][27][28] and HPLC methods. 14,[29][30][31] Also, BEN has been analyzed in the presence of its degradation product by HPLC.…”
Two validated, sensitive and highly selective stability-indicating methods were adopted for the simultaneous quantitative determination of antipyrine (ANT) and benzocaine HCl (BEN) in the presence of the degradation product of benzocaine HCl [p-aminobenzoic acid (PABA)].
“…1 (ethyl 4-aminobenzoat) is used as topical anesthetics [1]. Various approaches were announced for PHN determination like spectrophotometry [2, 3, 4, 5] HPLC [6, 7, 8], TLC [9], GC [10, 11] and capillary zone electrophoresis methods [12], whereas BEN was determined by spectrophotometry [13, 14, 15, 16, 17, 18], HPLC methods [19, 20, 21, 22, 23, 24]. Simultaneous quantification of PHN and BEN existing in otic drop formulation was announced in previous published studies by spectrophotometric [25, 26], HPLC [27, 28] and TLC [29] methods.Fig.…”
Four spectrophotometric approaches were performed to determine a binary combination of Phenazone and Benzocaine in pure powder form and in pharmaceutical formations. This investigation submits the application of four techniques contingent on the presence of the extended area of the spectra of one compound in the binary mixture, these methods include Absorptivity Centering (a-centering), Absorbance Subtraction (AS), Amplitude Modulation (AM) and Concentration Value (CV). The linearity range for the above-mentioned approaches was found to be 3.0–15.0 μg/mL for Benzocaine in a-centering method and 3.0–30.0 μg/mL for Benzocaine and Phenazone in other advanced methods. The four techniques were evaluated as per ICH criteria and were successfully utilized for the determination of Phenazone and Benzocaine existing in pharmaceutical formulations. All results gained by the submitted approaches were statistically compared with a previously published method, and no important differences were detected.
“…1 BE is official in USP 2 and BP 3 pharmacopeia. BE was determined by several methods including; spectrophotometry [16][17][18][19][20][21] , and HPLC. [22][23][24][25][26] HPLC method was also reported as a stability indicating method for BE.…”
Antipyrine and benzocaine are formulated together for the treatment of ear inflammation and to relieve pain. Four spectrophotometric methods were developed for the simultaneous determination of antipyrine (AN) and benzocaine (BE) in their combined dosage form. Method A depends on applying dual wavelength method where antipyrine was determined by measuring the absorbance at 254.1 and 309.1 nm (corresponding to zero difference of benzocaine), while the absorbance difference at 230.1 and 263.5 nm (corresponding to zero difference of antipyrine) was selected for benzocaine determination in the laboratory prepared spectrum. Method B depends on measuring the peak amplitude of first derivative at 305 nm for calculating benzocaine concentration then the total concentration of both drugs was determined using isoabsorptive point at 257.4 nm (antipyrine concentration was then calculated by subtraction). Method C is based on measuring the peak difference of the ratio spectra at Dp (239.1-285 nm) and Dp (301.4-250 nm) for the determination of antipyrine and benzocaine, respectively. Method D depends on measuring peak to peak amplitude of the first derivative of ratio spectra at (234.5 + 244.2 nm) and peak amplitude at 295.5 nm for the determination of antipyrine and benzocaine, respectively. The proposed methods were validated and applied for the analysis of antipyrine and benzocaine in their laboratory prepared mixtures and pharmaceutical formulation. Statistical comparison between the results of the proposed methods and those of the reported methods showed no significant difference. Ó 2016 Production and hosting by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/ 4.0/).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
